Effect of Topiroxostat on Urinary Albumin Excretion in Patients With eARly Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout: a Randomized, Placebo-controlled, Double-blind Phase 2a Trial

Trial Profile

Effect of Topiroxostat on Urinary Albumin Excretion in Patients With eARly Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout: a Randomized, Placebo-controlled, Double-blind Phase 2a Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Topiroxostat (Primary)
  • Indications Diabetic nephropathies; Hyperuricaemia
  • Focus Therapeutic Use
  • Acronyms UPWARD
  • Sponsors Sanwa Kagaku Kenkyusho
  • Most Recent Events

    • 10 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 17 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 18 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top